North America Infectious Disease Testing Market for Over 100 Tests: USA, Canada, Mexico--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review
This new report provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Canada, Mexico, US
Market Segmentation Analysis
- Sales and market shares of major suppliers of
infectious disease diagnostic products in major countries by test.
- Test and sales forecasts for 100 infectious disease diagnostic
assays by country, individual test and market segment:
- Review of market dynamics, trends,
structure, size, growth and major suppliers.
Current and Emerging Products
- In-depth examination of major diseases,
including their etiology, current diagnostic tests,
vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease
testing, including their operating
characteristics, features and selling prices.
- Assessment of emerging diagnostic technologies and their potential
applications for infectious disease testing.
- Companies developing or
marketing infectious disease diagnostic products
by individual test.
- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D.
Opportunities and Strategies for Suppliers
- Emerging opportunities for new instrumentation,
reagent systems, IT and other products with significant market
appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Contains 1,045 pages and 181 tables
- Beckman Coulter/Danaher
- Becton Dickinson
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- GSK Biologicals
- Leica Biosystems
- Ortho-Clinical Diagnostics
- Siemens Healthineers
- Takara Bio
- Thermo Fisher